Impact Biomedical (IBO) Finished Goods (2025 - 2026)
Impact Biomedical's (IBO) quarterly Finished Goods came in at $62000.0 in Q2 2026, down 87.24% on a YoY basis from $486000.0 in Q2 2025, and down 1.59% quarter-over-quarter from $63000.0 in Q1 2026.
Powered by 
Analysis
Impact Biomedical (IBO) Finished Goods (2025 - 2026) Analysis & Trends
Impact Biomedical (IBO) has reported Finished Goods for 2 consecutive years, with $62000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Finished Goods fell 87.24% year-over-year to $62000.0; the trailing twelve-month figure through Jun 2026 stood at $62000.0 (down 87.24% YoY), and the FY2025 full-year result was $63000.0, changed N/A from the prior year.
- Finished Goods slipped to $62000.0 in Q2 2026 per IBO's latest filing, from $63000.0 in the prior quarter.
- Across five years, Finished Goods topped out at $486000.0 in Q2 2025 and bottomed at $62000.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62,000.00 |
| Mar 31, 2026 | 63,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Sep 30, 2025 | 485,000.00 |
| Jun 30, 2025 | 486,000.00 |